PMID- 28397104
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20181202
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
VI  - 27
IP  - 9
DP  - 2017 Sep
TI  - Omeprazole Absorption and Fasting Gastrinemia After Roux-en-Y Gastric Bypass.
PG  - 2303-2307
LID - 10.1007/s11695-017-2672-z [doi]
AB  - PURPOSE: Roux-en-Y gastric bypass (RYGB) is one of the bariatric surgeries most 
      frequently performed worldwide. Since this operation may predispose to the 
      formation of peptic ulcer of the gastrojejunal anastomosis, the use of proton 
      pump inhibitors (PPI) is recommended during the first postoperative year. 
      However, so far, there is no detailed knowledge about the absorption of this 
      medication during the immediate postoperative period and consequently about its 
      effectiveness in blocking acid secretion. The objective was to assess the 
      possible endoscopic peptic changes, the absorption of omeprazole (OME), and the 
      status of fasting gastrinemia before and after RYGB operation. MATERIALS AND 
      METHODS: OME absorption, the production of its metabolites omeprazole sulfone 
      (OMES) and 5-hydroxyomeprazole (HOME), and basal (fasting) gastrinemia were 
      determined in patients submitted to RYGB before and 2 months after the operation. 
      Upper digestive endoscopy (UDE) was also performed before and 6 months after the 
      operation. RESULTS: Twenty patients were studied. Preoperatively, all these 
      patients had some peptic changes and 55% tested positive for Helicobacter pylori. 
      Six months after surgery, ten patients still showed endoscopic changes and one 
      patient tested positive for H. pylori. During the postoperative period, there was 
      a reduction of OME absorption and of the production of its metabolites 90 min 
      after administration of the drug, and reduction of serum gastrin levels. 
      CONCLUSION: The standard OME dose (40 mg) administered after bariatric surgery is 
      insufficient to achieve serum levels that can effectively block the production of 
      hydrochloric acid, permitting the formation of peptic injuries in many patients.
FAU - Collares-Pelizaro, Renata V A
AU  - Collares-Pelizaro RVA
AD  - Department of Surgery and Anatomy, Clinical Hospital, Faculty of Medicine, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Santos, Jose S
AU  - Santos JS
AD  - Department of Surgery and Anatomy, Clinical Hospital, Faculty of Medicine, 
      University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Nonino, Carla B
AU  - Nonino CB
AD  - Department of Clinical Analysis, Toxicology and Bromatology, Faculty of 
      Pharmaceutical Sciences, University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - dos Reis Dias, Larissa Alves
AU  - dos Reis Dias LA
AD  - Nutritional Division of the Department of Medical Clinic, Clinical Hospital, 
      Faculty of Medicine, University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Gaitani, Cristiane M
AU  - Gaitani CM
AD  - Nutritional Division of the Department of Medical Clinic, Clinical Hospital, 
      Faculty of Medicine, University of Sao Paulo, Ribeirao Preto, Brazil.
FAU - Salgado, Wilson Jr
AU  - Salgado W Jr
AD  - Department of Surgery and Anatomy, Clinical Hospital, Faculty of Medicine, 
      University of Sao Paulo, Ribeirao Preto, Brazil. wsalgado@fmrp.usp.br.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
RN  - 0 (Gastrins)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
EIN - Obes Surg. 2017 Aug 24;:. PMID: 28840530
EIN - Obes Surg. 2017 Dec;27(12 ):3351. PMID: 29047048
MH  - Adult
MH  - Anastomosis, Roux-en-Y
MH  - Fasting/blood
MH  - Female
MH  - Gastric Bypass/adverse effects/methods/*rehabilitation
MH  - Gastrins/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/blood/*metabolism/*surgery
MH  - Omeprazole/*pharmacokinetics/therapeutic use
MH  - Peptic Ulcer/metabolism/prevention & control
MH  - Proton Pump Inhibitors/*pharmacokinetics/therapeutic use
OTO - NOTNLM
OT  - 5-Hydroxyomeprazole
OT  - Bariatric surgery
OT  - ELISA
OT  - Gastrin
OT  - Liquid chromatography
OT  - Obesity
OT  - Omeprazole
OT  - Omeprazole sulfone
OT  - Proton pump inhibitors
OT  - Roux-en-Y gastric bypass
OT  - Upper digestive endoscopy
EDAT- 2017/04/12 06:00
MHDA- 2018/03/10 06:00
CRDT- 2017/04/12 06:00
PHST- 2017/04/12 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
PHST- 2017/04/12 06:00 [entrez]
AID - 10.1007/s11695-017-2672-z [pii]
AID - 10.1007/s11695-017-2672-z [doi]
PST - ppublish
SO  - Obes Surg. 2017 Sep;27(9):2303-2307. doi: 10.1007/s11695-017-2672-z.